This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen acción C6O
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de Clovis Oncology, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.023 |
| 52 Week High | €2.46 |
| 52 Week Low | €0.01 |
| Beta | 0.66 |
| 1 Month Change | 130.00% |
| 3 Month Change | -16.06% |
| 1 Year Change | -99.07% |
| 3 Year Change | -99.60% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.86% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| C6O | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 53.3% | 4.8% | -0.4% |
| 1Y | -99.1% | -16.0% | 3.4% |
Rentabilidad frente al sector: C6O underperformed the German Biotechs industry which returned -6.5% over the past year.
Rentabilidad vs. Mercado: C6O underperformed the German Market which returned 7.1% over the past year.
Volatilidad de los precios
| C6O volatility | |
|---|---|
| C6O Average Weekly Movement | 104.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: C6O's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: C6O's weekly volatility has increased from 91% to 105% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | https://www.clovisoncology.com |
Resumen de fundamentos de Clovis Oncology, Inc.
| Estadísticas fundamentales de C6O | |
|---|---|
| Capitalización bursátil | €2.18m |
| Beneficios(TTM) | -€226.19m |
| Ingresos (TTM) | €119.44m |
0.0x
Ratio precio-beneficio0.0x
Ratio precio-beneficio¿Está C6O sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de C6O | |
|---|---|
| Ingresos | US$133.02m |
| Coste de los ingresos | US$31.59m |
| Beneficio bruto | US$101.43m |
| Otros gastos | US$353.33m |
| Beneficios | -US$251.91m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.73 |
| Margen bruto | 76.25% |
| Margen de beneficio neto | -189.37% |
| Ratio deuda/patrimonio | -158.0% |
¿Cómo se ha desempeñado C6O a largo plazo?
Ver rendimiento histórico y comparativa